Acumen Pharmaceuticals (ABOS) Other Non-Current Assets (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Other Non-Current Assets of $231000.0 for Q1 2026, down 34.0% sequentially from $350000.0 in Q4 2025, and little changed YoY from $232000.0 in Q1 2025.
Acumen Pharmaceuticals (ABOS) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Other Non-Current Assets for 6 years, with the latest figure at $231000.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.43% year-over-year to $231000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231000.0 (changed 0.43% YoY) and the FY2025 annual result came in at $350000.0, down 27.98% from the prior year.
- Other Non-Current Assets retreated to $231000.0 in Q1 2026 per ABOS's latest filing, from $350000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $486000.0 in Q4 2024 and troughed at $79000.0 in Q1 2022.
- A 5-year average of $234562.5 and a median of $231500.0 in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets soared 978.57% in 2022, then tumbled 45.41% in 2025.
- Over 5 years, Other Non-Current Assets stood at $151000.0 in 2022, then surged by 54.3% to $233000.0 in 2023, then soared by 108.58% to $486000.0 in 2024, then dropped by 27.98% to $350000.0 in 2025, then tumbled by 34.0% to $231000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $231000.0, $350000.0, and $232000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 263,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 263,000.00 |
| Mar 31, 2026 | 231,000.00 |
| Dec 31, 2025 | 350,000.00 |
| Sep 30, 2025 | 232,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Mar 31, 2025 | 232,000.00 |
| Dec 31, 2024 | 486,000.00 |
| Sep 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 425,000.00 |
| Mar 31, 2024 | 234,000.00 |
| Dec 31, 2023 | 233,000.00 |
| Sep 30, 2023 | 189,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Mar 31, 2023 | 195,000.00 |
| Dec 31, 2022 | 151,000.00 |
| Jun 30, 2022 | 106,000.00 |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | 14,000.00 |
| Sep 30, 2021 | 13,000.00 |
| Jun 30, 2021 | 13,000.00 |